Search Results

The Anti-Neutrophil Cytoplasmic Antibodies (Ethanol-fixed) test system is an indirect immunofluorescence assay (IFA) for the qualitative and semi-quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) of the IgG isotype in human serum by manual fluorescence microscopy or with dIFine. The presence of ANCA in conjunction with other clinical and laboratory findings can be used to aid in the diagnosis of ANCA associated vasculitis (AAV). All suggested results obtained with dIFine must be confirmed by a trained operator.

The Anti-Neutrophil Cytoplasmic Antibodies (Formalin-fixed) test system is an indirect immunofluorescence assay (IFA) for the qualitative and semi-quantitative determination of anti-neutrophil cytoplasmic antibodies (ANCA) of the IgG isotype in human serum by manual fluorescence microscopy or with dIFine. The presence of ANCA in conjunction with other clinical and laboratory findings can be used to aid in the diagnosis of ANCA associated vasculitis (AAV). All suggested results obtained with dIFine must be confirmed by a trained operator.

Not Found

The provided FDA 510(k) clearance letter for "Anti-Neutrophil Cytoplasmic Antibodies (Ethanol-Fixed)" and "Anti-Neutrophil Cytoplasmic Antibodies (Formalin-Fixed)" from ZEUS Scientific does not contain the detailed information necessary to describe the acceptance criteria and the study that proves the device meets those criteria.

This document is primarily a clearance letter, confirming that the device is substantially equivalent to a predicate device and outlining regulatory guidelines and requirements. It mentions the "dIFine" system, which likely refers to an automated interpretation component, but it does not provide any specific performance data, study design, or methodology for demonstrating the device's accuracy or effectiveness.

Therefore, I cannot fulfill your request for the following information based solely on the provided text:

1. A table of acceptance criteria and the reported device performance: This information is not present.
2. Sample sized used for the test set and the data provenance: Not mentioned.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not mentioned.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not mentioned.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not mentioned. The letter states that "All suggested results obtained with dIFine must be confirmed by a trained operator," implying a human-in-the-loop, but no study details are provided.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not mentioned, although the statement about human confirmation suggests the primary use case is not standalone.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not mentioned.
8. The sample size for the training set: Not mentioned.
9. How the ground truth for the training set was established: Not mentioned.

To obtain this information, you would typically need to refer to the 510(k) Summary or the full 510(k) submission document, which often includes a detailed description of the validation studies conducted. The clearance letter itself is a summary of the FDA's decision, not the full technical dossier.

Ask a specific question about this device